Caribou Biosciences, INC DEF 14A proxy statements

Caribou Biosciences has issued its 2026 proxy statement, outlining director elections, auditor ratification, and a proposal to amend its certificate of incorporation to provide officer exculpation.

Caribou Biosciences is seeking stockholder approval for a reverse stock split to regain compliance with Nasdaq's minimum bid price rule after receiving a deficiency letter.

Caribou Biosciences has scheduled its 2025 Annual Meeting for June 12, 2025, and is seeking stockholder votes on director elections, auditor ratification, a potential reverse stock split, and meeting adjournment if necessary.

Caribou Biosciences seeks stockholder approval for a reverse stock split to maintain its Nasdaq listing and improve stock marketability.

Caribou Biosciences has scheduled its 2024 Annual Meeting for June 13, 2024, and is urging stockholders to vote on key proposals, including the election of directors and ratification of the company's accounting firm.

Caribou Biosciences will hold its 2024 annual meeting of stockholders virtually on June 13, 2024, to elect directors and ratify the appointment of its independent accounting firm.